TITLE

A Cohort Study of Nevirapine Tolerance in Clinical Practice: French Aquitaine Cohort, 1997--1999

AUTHOR(S)
Bonnet, F.; Lawson-Ayayi, S.; Thiébaut, R.; Ramanampamonjy, R.; Lacoste, D.; Bernard, N.; Malvy, D.; Bonarek, M.; Djossou, F.; Beylot, J.; Dabis, F.; Morlat, P.
PUB. DATE
November 2002
SOURCE
Clinical Infectious Diseases;11/15/2002, Vol. 35 Issue 10, p1231
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
We performed a retrospective study to evaluate, under routine circumstances, the tolerance and immunovirological changes associated with antiretroviral regimens that contain nevirapine in 137 patients (88% were antiretroviral experienced). During a mean follow-up of 11 months, 33% of patients reported side effects attributed to nevirapine, and 21% discontinued treatment because of poor tolerance. Administration of antihistamines or corticosteroids at the initiation of treatment was not protective against adverse events (relative risk, 0.82; 95% confidence interval, 0.49-1.38). The proportion of patients with hepatitis C virus (HCV) and/ or hepatitis B virus (HBV) coinfection who had alanine aminotransferase levels of >100 IU/L increased from 19.4% at baseline to 42.9% at month 12 of follow-up (P = .02). We noticed a significant increase of the proportion of patients with total cholesterol levels of >5.5 mM (P = .02). We have shown that there is a high level of discontinuation of nevirapine therapy in clinical practice and that side effects were not prevented by administration of antihistamines or corticosteroids. Coinfection with HCV or HBV increased the risk of hepatotoxicity, which lead to the cautious use of nevirapine for such patients.
ACCESSION #
8609013

 

Related Articles

  • Hepatotoxicity Associated With Antiretroviral in Adults Infected With Human Immunodeficiency Virus and the Role of Hepatitis C or B Virus Infection. Sulkowski, Mark S.; Thomas, David L.; Chaisson, Richard E.; Moore, Richard D. // JAMA: Journal of the American Medical Association;1/5/2000, Vol. 283 Issue 1, p74 

    Reports on experiments designed to ascertain if incidence of severe hepatotoxicity during antiretroviral therapy is similar for all antiretroviral drug combinations. Efforts to define the role of chronic viral hepatitis in its development; Context; Objectives; Design; Setting; Patients; Main...

  • Treat HIv-1 Infected with at Least Two Antiretrovirals.  // Kidney;Sep/Oct99, Vol. 8 Issue 5, p203 

    Discusses an abstract of the article, entitled `Effect of hemodialysis and antiretroviral therapy on plasma viral load in HIV-1 infected hemodialysis patients,' by T.S. Ahuja, N. Niaz. A. Velasco and others.

  • VIRACEPT COMBINATIONS STUDIES.  // AIDS Patient Care & STDs;Jun98, Vol. 12 Issue 6, p495 

    Presents information on the fifth Conference on Retroviruses and Opportunistic Infections in Chicago in 1998. Summarization of the results from clinical trials of the drug Viracept; Use of the drug with other protease inhibitors and anti-human immunodeficiency virus (HIV) drugs; Evaluation of...

  • Stavudine Once Daily. Cheer, S.M.; Goa, K.L. // Drugs;2002, Vol. 62 Issue 18, p2667 

    â–´ Stavudine administered once daily is a nucleoside analogue reverse transcriptase inhibitor. â–´ The efficacy (reduction in viral load and increase in CD4+ lymphocyte counts from baseline) of stavudine once daily-containing triple therapy was similar to that of stavudine immediate...

  • Abacavir Hypersensitivity Reaction. Hewitt, Ross G. // Clinical Infectious Diseases;4/15/2002, Vol. 34 Issue 8, p1137 

    A hypersensitivity reaction occurs in association with initiation of abacavir therapy as part of combination antiretroviral therapy in ∼3.7% of patients. The reaction is possibly the result of a combination of altered drug metabolism and immune dysfunction, which is poorly understood....

  • Approaching Eradication of Highly Active Antiretroviral Therapy-Persistent Human Immunodeficiency Virus Type 1 Reservoirs with Immune Activation Therapy. Kulkosky, Joseph; Pomerantz, Roger J. // Clinical Infectious Diseases;12/15/2002, Vol. 35 Issue 12, p1520 

    Highly active antiretroviral therapy (HAART) has dramatically altered the human immunodeficiency virus type 1 (HIV-1) pandemic in the developed world. Most patients treated with HAART will maintain clinically undetectable plasma virus loads with concomitant dramatic decreases in mortality and...

  • Immune Reconstitution Cryptococcosis after Initiation of Successful Highly Active Antiretroviral Therapy. Jenny-Avital, Elizabeth R.; Abadi, Maria // Clinical Infectious Diseases;12/15/2002, Vol. 35 Issue 12, p128 

    Five of 10 patients who commenced successful highly active antiretroviral therapy (HAART) for infection with human immunodeficiency virus type 1 (HIV-1) concurrent with or soon after a diagnosis of cryptococcal infection experienced clinical events characterized by sterile inflammation. Two...

  • Failure of a prospective trial to detect cytomegalovirus retinitis after initiation of highly... Uphold, Constance R.; Smith, Fran // AIDS Patient Care & STDs;Dec98, Vol. 12 Issue 12, p907 

    Determines the incidence of cytomegalovirus (CMV) retinis prior to and after initiation with highly active antiretroviral therapy (HAART). Decrease in viral loads and increase in CD4+ T-cell counts after starting HAART; Non-occurrence of CMV retinis among patients receiving HAART; Development...

  • SELF-REPORTED ADHERENCE NOT RELIABLE.  // AIDS Patient Care & STDs;Jan1999, Vol. 13 Issue 1, p59 

    Reports that self-reporting of adherence to various anti-retroviral therapies is not a reliable method when used alone. Electronic monitoring of adherence.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics